DEA Archived Press Releases

Press Releases before January 20, 2025
9 Results - Showing 1 to 9
PRESS RELEASE

Sweeping DEA Operation Targets Pharmacy Burglaries and the Illegal Sale of Addictive Prescription Medications

WASHINGTON – The U.S. Drug Enforcement Administration has seen an increase in burglaries at independent pharmacies across the country. Nearly 900 burglaries involving the theft of controlled substances were reported to DEA in 2023. Stolen prescription medications adversely impact these small businesses while also putting patients and the community at...
PRESS RELEASE

DEA Announces Settlement with Morris & Dickson Co., LLC

WASHINGTON, D.C. – The U.S. Drug Enforcement Administration announced today a settlement with pharmaceutical distributor Morris & Dickson Co., LLC for failing to maintain effective controls against diversion of controlled substances, including failure to report to DEA thousands of unusually large orders of oxycodone and hydrocodone. Morris & Dickson, which...
PRESS RELEASE

DEA Executes Operation Bottleneck to Prevent the Diversion of Controlled Substances and Keep Communities Safe

WASHINGTON – Today, the U.S. Drug Enforcement Administration announced administrative actions against six DEA-registered companies which, together, failed to account for more than a million doses of opioids. Under DEA initiative “Operation Bottleneck,” DEA served an Immediate Suspension Order and five Orders to Show Cause over a one-month period from...
PRESS RELEASE

DEA, SAMHSA Extend COVID-19 Telemedicine Flexibilities for Prescribing Controlled Medications for Six Months While Considering Comments from the Public

WASHINGTON – Today, ahead of the expiration of the COVID-19 Public Health Emergency (PHE), the Drug Enforcement Administration (DEA) and the Substance Abuse and Mental Health Services Administration (SAMHSA) issued the “Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications” – a temporary rule that extends telemedicine flexibilities...
PRESS RELEASE

DEA Announces Proposed Rules for Permanent Telemedicine Flexibilities

WASHINGTON - Today, the Drug Enforcement Administration announced proposed permanent rules for the prescribing of controlled medications via telemedicine, expanding patient access to critical therapies beyond the scheduled end of the COVID-19 public health emergency. The public will be able to comment for 30 days on the proposed rules. The...
PRESS RELEASE

DEA Serves Order to Show Cause on Truepill Pharmacy for its Involvement in the Unlawful Dispensing of Prescription Stimulants

WASHINGTON -- Today, DEA served an Order to Show Cause on Truepill, a retail pharmacy that is alleged to have wrongfully filled thousands of prescriptions for stimulants used in the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). Truepill was the pharmacy for telehealth companies, including Cerebral, that marketed ADHD treatments, including...
PRESS RELEASE

MS-13 Honduras Leader and Drug Supplier Charged

WASHINGTON, D.C. - Damian Williams, the United States Attorney for the Southern District of New York, John J. Durham, Director of Joint Task Force Vulcan (“JTFV”), Anne Milgram, Administrator of the Drug Enforcement Administration (“DEA”), Jay Greenberg, Acting Assistant Director of the Criminal Investigative Division of the Federal Bureau of...
PRESS RELEASE

National Health Care Fraud Enforcement Action

WASHINGTON – The Department of Justice announced today criminal charges against 138 defendants, including 42 doctors, nurses, and other licensed medical professionals, in 31 federal districts across the United States, for their alleged participation in various healthcare fraud schemes that resulted in approximately $1.4 billion in alleged losses. The charges...
PRESS RELEASE

Omnicare Inc. agrees to pay more than $15 million to resolve allegations it improperly dispensed narcotics at long-term care facilities

WASHINGTON – Omnicare Inc., a subsidiary of CVS Health and a leading provider of pharmacy services to long-term care facilities, has agreed to pay the United States a $15.3 million civil penalty to resolve allegations that it violated federal law by allowing opioids and other controlled substances to be dispensed...